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Up-regulation of heat shock protein 70 (HSP70) could be elicited primarily by heat in former studies, and this was
proved to be associated with cancer progression. Burkitt's lymphoma is one of highly aggressive B-cell
non-Hodgkin’s lymphoma and is one of the fastest growing human tumors. To investigate the effect of HSP70
expression on the sensitivity of human Burkitt lymphoma cells (Raji cells) to chemotherapy and its role in the
involvement of PI3K/AKT pathway, we evaluated the effects of LY294002, a PI3K inhibitor, on the expression of
HSP70 and cell sensitivity to adriamycin (ADM) or cisplatin (DDP). In present study, expressions of HSP70, AKT and
phosphorylated AKT (p-AKT) in Raji cells were measured by Western-Blot. Apoptosis index of Raji cells was
examined by flow cytometry. Cytotoxicities of adriamycin (ADM) and cisplatin (DDP) were determined by WST-8
assay. We found that hyperthermia (42 degrees for 1 hour) up-regulated the expression of HSP70 expression and
blockade of PI3K/AKT pathway down-regulated HSP70 expression in Raji cells. Compared to cells treated with ADM
or DDP alone, hyperthermia protected cells from chemotherapy while LY294002 enhanced sensitivity of Raji cells to
chemotherapy. Our results suggested down-regulation of HSP70 expression by blockade of PI3K/AKT pathway
maybe responsible for the increased sensitivity of Raji cells to chemotherapy. Targeting PI3K/AKT pathway or
inhibiting HSP70 expression may be beneficial for chemotherapy treatment of Burkitt lymphoma patients.
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Burkitt lymphoma (BL) is an aggressive, highly prolifera-
tive lymphoma, in spite of its low incidence throughout
most of the world [1]. It can often be cured by intensive
chemotherapy, but the toxicity of such therapy precludes
its use in the elderly and in patients with endemic BL in
developing countries [2]. Novel therapeutic strategies are
required to overcome drug toxicity following conven-
tional treatments.
HSP70 is an important cellular chaperone. Its expres-
sion is induced by a wide variety of physiological and en-
vironmental insults and allows the cells to survive lethal
conditions [3,4]. HSP70 is over-expressed in various human
cancers, including pancreatic cancer [5], bladder cancer [6],* Correspondence: xinwang55@yahoo.com.cn
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reproduction in any medium, provided the orcolon cancer [7], breast cancer [8] and non-Hodgkin’s
lymphoma [9]. In cancer cells, over-expression of HSP70 is
thought to provide a survival advantage because it is able to
interact with multiple components of both the caspase
dependent and independent apoptotic pathways [10]. The
expression of HSP70 has been routinely associated with
cancer progression, therapy responses and poor prognosis
in multiple forms of cancers [11,12] and it can be used as a
novel biomarker for early detection of cancers. HSP70 also
has emerging as a therapy target in cancers recently. Gene
silencing of HSP70 inhibits human cancer cell growth
in vitro and in vivo [13] and leads to loss of invasion in a
variety of cancer cells [14].
Activation of heat shock factor 1(HSF1) is the key step
in the induction of HSP70 expression. HSF1 exists as an
inactive monomer in a complex with HSP40/HSP70 and
HSP90. In such stress as elevated temperature, HSF1 is
released from the chaperone complex and transported
into the nucleus where it is hyperphosphorylated andd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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leading to rapid induction of these important molecular
chaperones [3]. Recently, studies revealed the abolishment
of serine473 phosphorylation in Akt could significantly re-
duce its kinase activity in CML cells. Inactivation of Akt
pathway subsequently blocked serine9 phosphorylation of
Gsk3β. Active non-phosphorylated Gsk3β rendered HSF1
transcriptionally inactive and reduced HSP70 production.
And blocking PI3K/Akt activity also be demonstrated
could induce the similar effects on HSP70 expression [15].
Given the role of HSP70 in tumors and the involvement
of PI3K/Akt activity in HSP70 expression, it is reasonably
plausible that blockade of PI3K/Akt pathway maybe affect
HSP70 production and then up-regulate chemotherapy
sensitivity in tumor cells. In present study, we demon-
strated that hyperthermia treatment (HT) induced HSP70
expression was mediated by PI3K/AKT pathway in Raji
cells. Furthermore, blocking of PI3K/AKT pathway could
down-regulate HSP70 expression, inhibit cancer cells sur-
vival and promote cells apoptosis when co-treated with
ADM or DDP. The decrease of HSP70 expression maybe
at least partially responsible for the increased chemother-
apy sensitivity of Raji cells. Targeting PI3K/AKT pathway
may provide new method to improve chemotherapy ef-
fects in cancer patients.
Materials and methods
Chemicals
LY294002, a PI3K inhibitor (CST,Danvers, MA, USA),
was dissolved in 100% dimethyl sulfoxide (DMSO) (Sigma,
St. Louis, MO, USA) and stored at -20°C. The stock con-
centration was 10 mmol/L and the final concentration of
DMSO in medium did not exceed 0.05%. At this level,
DMSO did not influence cell viability. Adriamycin (ADM)
was purchased from Shanghai Pharma, China and cis-
platin (DDP) was obtained from Qilu Pharmaceutical co.,
LTD, Shandong, China. They were dissolved in deionized
water to a concentration of 1.0 mg/ml, and then were di-
luted to defined concentrations for further experiment.
Cell culture
Raji cells were purchased from Shanghai Institutes for
Biological Sciences (SIBS, CAS, Shanghai, China) and
maintained in RPMI-1640 medium (Gibco, Carlsbad, CA,
USA) containing 10% heat-inactivated fetal bovine serum
albumin (Sijiqing Biological Engineering Materials Co.,
Ltd., Hangzhou, Zhejiang, China), penicillin (100 U/ml),
and streptomycin (100 mg/ml) in the 95% humidified in-
cubator with 5% CO2 at 37°C. To explore the effects of
HT on cell growth and HSP70 expression, Raji cells were
seeded on coverslips in 24-well microplates and cultured
at 42.0°C for 1 hour, and then immediately returned to
37.0°C for continuous incubation of 2, 4, 8 or 24 hours.
To analyze the effects of LY294002 on cell growth andexpression of HSP70, Raji cells were cultured with or
without LY294002 (5 μM, 10 μM, 20 μM, 40 μM,) for 8 h.
For experiments with ADM or DDP treatment, Raji cells
were treated with LY294002 or HT (42.0°C for 1 hour) be-
fore being exposed to chemicals. Cells were then received
continuous incubation of 8 hours at 37.0°C. At last, cells
were collected for apoptosis assay and immunoblot ana-
lysis of HSP70.
Flow cytometric analysis
After treatment of Raji cells with LY294002 / HT, or to-
gether with ADM or DDP for the indicated periods,
Apoptosis index (AI) were analyzed by staining the cells
with fluorescein isothiocyanate (FITC)–annexin V and pro-
pidium iodide (PI), according to the manufacturer’s instruc-
tions (Jingmei Biotech, Shenzhen, China). Briefly, an aliquot
of 105 cells was incubated with FITC–annexin V and PI for
15 minutes at room temperature in the dark. Cells were
then immediately analyzed by a Beckman Coulter EPICS
XL flow cytometer (Beckman Coulter, Fullerton, CA, USA)
and variables were analyzed by Expo 32 software.
Immunoblot analysis
Total protein was extracted from Raji cells in different
groups using RIPA and 1% PMSF (CST,Danvers, MA,
USA). HSP70 monoclonal antibody was purchased from
R&D Systems (Minneapolis, MN, USA). Akt and p-Akt
monoclonal antibody were purchased from Cell Signal-
ing Technology (Danvers, MA, USA). The measurement
of protein concentrations and detailed procedures of im-
munoblot analysis were described previously [16].
Assessment of cell viability
After received LY294002 or hyperthermia treatment as
described previously, cells (1 × 105 ) were seeded into
96-well plates. ADM and DDP were then added into cul-
tures. Twenty-four hours later, 10 μL CCK-8 (Dojindo
Molecular Technologies, Kumamoto, Japan) was added
to each well, and the cells were incubated at atmosphere
for 4 hours. The absorbance at 450 nm was then mea-
sured using a microplate reader. Percentage of survival cell
was calculated as follows: (Aexp group-Ablank/Acontrol-
Ablank) × 100%.
Statistics
Analyses of data were performed by using SPSS15.0 for
Windows. Data are presented as the mean ± SD. Differ-
ences in the results for two groups were evaluated by
Student’s t-test. Half maximal inhibitory concentration
(IC50) was analyzed with the linear regression. All ex-
periments were repeated at least three times. All differ-
ences were considered to be statistically significant when
the P value was less than 0.05.
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Effects of HT and LY294002 on cell apoptosis and
expression of HSP70
Raji cells were used for the present study. We found that
the apoptosis rate of cells in HT treated cells was similar
to that in cells without HT treatment (data was not shown).
However, HSP70 expression was enhanced obviously by
exposure of HT and increased in a time-dependent man-
ner in the first 8 hours. After 24 hours, the expression of
HSP70 was still significantly higher than untreated controls
(P < 0.05) (Figure 1A).
LY294002, a PI3K inhibitor, was used to block PI3K/
AKT pathway. In order to explore the apoptosis-inducing
effect of LY294002 on Raji cells, we detected the apoptosis
rate of Raji cells after treatment with LY294002. As shown
in Figure 1B, there was no difference in control group and
LY294002 group when its concerntration was at 5 μM,
10 μM, and 20 μM. However, LY294002 at 40 μM could
increase apoptosis rate obviously. In our following ex-
periment, we used 20 μM of LY294002 to analyze its effect
on expression of HSP70 and p-AKT in Raji cells. We
found that HT could significantly upregulate the expres-
sion of HSP70 and p-AKT expression obviously while
LY294002 (20 μM) could inhibit their expression dramat-
ically (P < 0.05) (Figure 1C). These results showed thatFigure 1 Effects of HT and LY294002 on expression of HSP70 and cel
they were returned to 37.0°C for the indicated time of recovery. The expres
cells induced by LY294002 at indicated concentration was measured by FA
returned to 37.0°C for 8 hours or received LY294002 (20 μM) teratment for
by Western-Blot.expression of HSP70 and activation of AKT (p-AKT) were
attenuated significantly by LY294002 at the concentrations
of 20 μM.
DDP induced apoptosis was protected by HT and
promoted by LY294002
To determine whether PI3K/AKT pathway and HSP70
protein expression were involved in the cancer cell sen-
sitivity to chemotherapy, cells were incubated with
LY294002 (20 μM) or HT treatment (42.0°C for 1 hour)
before they were exposured to chemicals. As shown in
Figure 1A, 42.0°C was enough to induce the expression
of HSP70. In addition, 20 μM of LY294002 could inhibit
HSP70 expression dramatically and has no effect on Raji
cells apoptosis. DDP at different concentrations was added
into the medium of Raji cells, HT treated cells and
LY294002 treated cells. After incubated with DDP for
8 hours, cells were collected and cell apoptosis index was
analyzed by flow cytometery (Figure 2). We showed that
cell apoptosis was induced by DDP in a concentration-
dependent manner in DDP group (14.1 ± 0.5% at 5 μg/ml,
16.9 ± 1.14% at 10 μg/ml, P < 0.01) (Figure 2A, B), while the
apoptotic cells in HT +DDP group was not increased with
the increasing of DDP concentration (9.73 ± 0.28% at 5 μg/
ml, 10.50 ± 0.85% at 10 μg/ml, P > 0.05) (Figure 2C, D). Inl apoptosis. (A) Raji cells were cultured at 42.0°C for 1 hour and then
sion of HSP70 was detected by Western-Blot. (B) Apoptosis rate of Raji
CS. (C) Raji cells were cultured at 42.0°C for 1 hour and then they were
8 hours. Expression of HSP70 and p-AKT in Raji cells were measured
Figure 2 Apoptosis induced by HT, LY294002 and DDP. (A) Apoptosis of Raji cells in HT + DDP(5 μg/ml) group; (B) Apoptosis of Raji cells in
HT + DDP(10 μg/ml)group; (C) Apoptosis of Raji cells in DDP(5 μg/ml)group; (D) Apoptosis of Raji cells in DDP(10 μg/ml)group; (E) Apoptosis of
Raji cells in LY294002 + DDP(5 μg/ml)group; (F) Apoptosis of Raji cells in LY294002 + DDP(10 μg/ml)group.
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cells were 25.2 ± 0.42% and 31.5 ± 0.37% respectively when
the concentration of DDP were 5 μg/ml and 10 μg/ml(Figure 2E, F). Furthermore, when DDP concentration was
equal, the apoptosis rate in LY294002 +DDP group was
significantly higher than DDP group and the percentage of
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than DDP group (P < 0.05). These results indicated that HT
contributed to chemotheapeutic tolerance of Raji cells,
while LY294002 promoted DDP induced cell apoptosis.HT protected Raji cells from chemotherapy while
LY294002 enhanced their sensitivity to chemotherapy
Besides the effects of HT and LY294002 on cell apop-
tosis, other mechanisms in cell growth caused by HT
and LY294002 were also explored. We next examined
cell survival by WST-8 assay. As shown in Figure 3A,
cell viability were inhibited by ADM in a concentration-
dependent manner. Raji cells in HT+ADM group showed
more resistant to ADM than ADM group and IC50 in-
creased from 4.5 μg/ml to 15.9 μg/ml. When treated withFigure 3 Effects of HT and LY294002 on ADM and DDP induced
cytotoxicity. WST-8 assay was used to detect survival rates of Raji
cells in indicated groups. Cell viability were inhibited by ADM in a
concentration-dependent manner. Raji cells in HT + ADM group
(RH gropup) showed more resistant to ADM than ADM group
(R group). When treated with LY294002 and ADM (RL group), Raji
cells were more sensitive to ADM (A). Similar phenomenon was also
observed when Raji cells were treated with DDP (B).LY294002 and ADM, Raji cells were more sensitive to
ADM and the IC50 was 3.6 μg/ml. Similar phenomenon
was also observed when Raji cells were treated with DDP.
The IC50 in DDP group, HT+DDP group and LY294002 +
DDP group were 5.2 μg/ml, 10.1 μg/ml and 2.6 μg/ml re-
spectively (P < 0.05) (Figure 3B).
Discussion
In this study, we observed that hyperthermia activated
the expression of HSP70 in Raji cells. High expression of
HSP70 was associated with lower apoptosis rate and re-
sistance to chemotherapy drugs. Blockade of PI3K/AKT
pathway not only inhibited HSP70 expression, but also
contributed to chemotherapy sensitivity of Raji cells. Our
findings suggested targeting PI3K/AKT/HSP70 pathway
may decrease chemotherapy drugs dosage and overcome
drugs resistance in Raji cells.
HSP70, one of the most important members of HSPs
family, its up-regulation is known to occur as a part of
the cellular defense system against environmental stresses
such as heat shock, oxidative stress, or treatments with
chemical agents. Previous studies indicated that Hsp70
played an important role in the control of cell cycling
and growth. Up-regulation of HSP70 also has been shown
to contribute to cancer cell survival via multiple anti-
apoptotic functions [17]. HSP70 inhibits p53 [18] at the
premitochondrial level [19], prevents mitochondrial outer
membrane permeabilization (MOMP) by blocking BAX
translocation and inhibit the release of cytochrome at the
mitochondrial level [20,21], blocks the recruitment of
procaspases 9 and 3 to the apoptosome complex, and the
assembly of functional apoptosome at the postmitochon-
drial stage [22]. It also inhibits the activation of AIF and
JNK, which induce apoptosis in a caspases-independent
way [23,24]. These findings indicated a distinct and exten-
sive anti-apoptotic function of HSP70.
Accumulating evidences indicated that hyperthermia
induced HSP70 expression was related with chemotherapy
resistance [25]. Moreover, Behnsawy et al had proved that
the expression of HSP70 was correlated with cell survival
when treated with chemotherapy [26]. In acute myeloid
leukemia and acute lymphoblastic leukemia, HSP70 is an
indicator for poor prognosis [27]. However, the precise
mechanism of Hsp70 in lymphoma cell survival and che-
motherapy resistance remains unclear. In the study, we
demonstrated that hyperthermia induced HSP70 expression
and protected Raji cells against ADM and DDP treatment.
The induction of HSP70 in response to various stimuli
is mainly regulated by the activation of HSF1 [28]. Recent
studies have showed that PI3K/AKT signal pathway was
involved in the induction of HSP70 expression [29,30].
This regulation might rely on the fact that the activation
of AKT inhibited GSK-3β [31], and the inhibition of
GSK-3β could activate HSF1. In our study, we blocked
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the altered expression of HSP70 in Raji cells. Our results
indicated the blockade of PI3K/AKT signaling pathway
inhibited HSP70 expression obviously. However, some
studies demonstrated that these signal cascades were not
found in either lens endothelial cells nor U937 cells
under certain conditions [32,33]. These contradictory
phenomenons might be incriminated to cell heterogen-
eity as well as different disposal conditions.
PI3K/Akt signaling pathway is frequently activated in
malignant diseases, including many hematologic malignan-
cies [34] and contributes to tumor cell survival [35-38].
The up-regulation of this signal pathway was also sug-
gested to increase drug resistance [39], but the underlying
mechanism is not fully proved. In this study, we confirmed
the existence of PI3K/AKT/HSP70 pathway in Raji cells.
Blockade of PI3K/AKT pathway not only inhibit HSP70
expression, but also promote cell sensitivity to chemother-
apy. Given the relationship between HSP70 expression
and chemotherapy resistance, we concluded that down-
regulation of HSP70 was at least partly responsible for the
promotion of Raji cells sensitivity to chemotherapy. Inhib-
ition of HSP70 may be an encouraging method to over-
come chemotherapy resistance.
Antisense HSP70 oligomer and HSP70 siRNA have been
used to induce low expression of HSP70 in different kinds
of cells and resulted higher apoptosis rate [40,41]. How-
ever, there are still some problems in their clinical appli-
cation. Quercetin, a kind of flavanoid, inhibited HSPs
expression in many kinds of cancer cells [42,43]. Cells be-
came more susceptible to apoptosis when treated with
quercetin followed by hyperthermia, chemotherapy or
radiotherapy [44-46]. But quercetin showed significant
toxicity even used as a signal agent, which largely limited
its clinical application. HSP90, another important member
of HSPs family, is closely related with cancer treatment.
One of its specific inhibitor, 17-allylamino-demethoxy-
geldanamycin (17-AAG), had been presented in the com-
pleted stage I clinical trial and demonstrated a favorable
therapeutic effect. Another inhibitor PU-H71 has demon-
strated considerable anti-tumor activity in diffused large B
cell lymphoma and multiple myeloma [47]. So far there is
no specific small-molecule HSP70 inhibitor which is avail-
able comparable with 17-AAG.
In summary, we documented that PI3K/AKT/HSP70
pathway existed in Raji cells and revealed an intriguing
mechanism that down-regulation of HSP70 was responsible
for the promotion of sensitivity to chemotherapy in Raji
cells. Targeting PI3K/AKT pathway or inhibiting HSP70
expression may be an encouraging method to overcome
chemotherapeutic resistance.Competing interest
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